Simultaneous liquid chromatography-mass spectrometry quantification of urinary opiates, cocaine, and metabolites in opiate-dependent pregnantwomen in methadone-maintenance treatment

Journal of Analytical Toxicology

Volumn 34, Issue 1, 2010, Pages 17-25

  Shakleya, Diaa M ^a   Dams, Riet ^b   Choo, Robin E ^c   Hendree, Jones ^d   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b University of Pittsburgh ^*  (Italy)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANHYDROECGONINE METHYL ESTER; BENZOYLECGONINE; BENZOYLNORECGONINE; COCAINE; CODEINE; CODEINE 6 GLUCURONIDE; DIAMORPHINE; DRUG METABOLITE; ECGONINE; ECGONINE ETHYL ESTER; ECGONINE METHYL ESTER; HOMOCOCAINE; M HYDROXYBENZOYLECGONINE; M HYDROXYCOCAINE; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 ACETATE; MORPHINE 6 GLUCURONIDE; NORCOCAETHYLENE; NORCOCAINE; NORCODEINE; NORMORPHINE; NOSCAPINE; OPIATE; PAPAVERINE; PENTO HYDROXYBENZOYLECGONINE; PENTO HYDROXYCOCAINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG SCREENING; DRUG URINE LEVEL; FEMALE; HEROIN DEPENDENCE; HUMAN; LIQUID CHROMATOGRAPHY; MAINTENANCE THERAPY; MASS SPECTROMETRY; OPIATE ADDICTION; PREGNANT WOMAN; QUANTITATIVE ANALYSIS; RELAPSE; SUBSTANCE ABUSE; URINALYSIS;

EID: 75749092990     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.1.17     Document Type: Article

References (52)

1. S. Shawla. 2008World Drug Report, United Nations Publication. United Nations Office on Drugs and Crime, Vienne, Austria.
2. T. Brettell, J. Butler, and R. Saferstein. Forensic science. Anal. Chem. 77: 3839-3860 (2005).
3. K. Wolff, M. Farrell, J. Marsden, M. Monteiro, R. Ali, S. Welch, and J. Strang. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction 94: 1279-1298 (1999).
4. A. Alnajjar, A. Idris, M. Multzenberg, and B. McCord. Development of a capillary electrophoresis method for the screening of human urine for multiple drugs of abuse. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 856: 62-67 (2007).
5. L. Avois, P. Mangin, and M. Saugy. Concentrations of nandrolone metabolites in urine after the therapeutic administration of an ophthalmic solution. J. Pharm. Biomed. Anal. 44: 173-179 (2007).
6. M. Petek and A. Vordoljak. Qualitative and quantitative gamma-hydroxybutyrate analysis. Arh. Hig. Rada. Toksikol. 57: 397-404 (2006).
7. P. Ondra, K. Zednikova, and I. Valka. Detection and determination of abused hallucinogens in biological material. Neuro. Endocrinol. Lett. 27: 125-129 (2006).
8. W. Cheng, K. Ng, K. Chan,V. Mok, and B. Cheung. Roadside detection of impairment under the influence of ketamine-evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci. Int. 170: 51-58 (2007).
9. T. Ishida, K. Kudo, H. Inoue, A. Tsuji, T. Kojima, and N. Ikeda. Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography -mass spectrometry. J. Anal. Toxicol. 30: 468-477 (2006).
10. F. Musshoff, J. Trafkowski, and B. Madea. Validated assay for the determination of markers of illicit heroin in urine samples for the control of patients in a heroin prescription program. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811: 47-52 (2004).
11. R. Kronstrand, T. Selden, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27: 464-470 (2003).
12. R. Dams, C. Murphy, W. Lambert, and M. Huestis. Urine drug testing for opiates, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17: 1665-1670 (2003).
13. M. Huestis, E. Cone, C. Wong, A. Umbricht, and K. Preston. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J.Anal. Toxicol. 24: 509-521 (2000).
14. L. Rivier. Techniques for analytical testing of unconventional samples. Best Practice Res. Clin. Endocrinol. Metab. 14: 147-165 (2000).
15. M. Vandevenne, H. Vandenbussche, and A. Verstraete. Detection time of drugs of abuse in urine. Acta Clin. Belg. 55: 323-333 (2000).
16. G. Ellis, M. Mann, B. Judson, N. Schramm, and A. Tashchian. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin. Pharmacol. Ther. 38: 572-578 (1985).
17. A. Salmon, Z. Goren,Y. Avissar, and H. Soreq. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin. Exp. Pharmacol. Physiol. 26: 596-600 (1999).
18. L. Antonilli and F. Semeraro. High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology 170: 200-204 (2003).
19. C. Meadway, S. George, and R. Braithwaite. A rapid GCMS method for the determination of dihydrocodeine, codeine, norcoseine, morphine, normorphine and 6-MAM in urine. Forensic Sci. Int. 127: 136-141 (2002).
20. S. Paterson, N. Lintzeris, T. Mitchell, R. Cordero, L. Nestor, and J. Strang. Validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of opiate dependence. Addiction 100: 1832-1839 (2005).
21. D. Bourquin, P. Bundeli, T. Lehmann, and R. Brenneisen. Diacetylmorphine and its metabolites in plasma by HPLC with diode array and atmospheric pressure ionization mass spectrometric detection. J. Liq. Chrom. Rel. Technol. 22: 2663-2674 (1999).
22. A. Moffat. Clarke's Analysis of Drugs and Poisons, 3rd ed. Pharmaceutical Press, London, U.K., 2004.
23. SAMHSA, Mandatory Guidelines for Federal Workplace Drug Testing Programs, 1994, Substance Abuse and Mental Health Services Administration, HHS, Rockville, MD.
24. SAMHSA, Mandatory Guidelines for Federal Workplace Drug Testing Programs, 1998, Substance Abuse and Mental Health Services Administration, HHS, Rockville, MD.
25. H. Fitzsimons, M. Tuten,V.Vaidya, and H. Jones. Mood disorders affect drug treatment success of drug-dependent pregnant women. J. Subst. Abuse Treat. 32: 19-25 (2007).
26. M. Chisolm, M. Tuten, E. Pfeil, E. Strain, and H. Jones. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am. J.Addict. 18: 422-429 (2009).
27. M. Tuten, S. Heil, K. O'Grady, H. Fitzsimons, M. Chisolm, and H. Jones. Methadone-maintained pregnant patients and current mood disorder: delivery and neonatal outcomes. Am. J. Drug Alcohol Abuse, in press.
28. H. Jones, N. Haug, K. Silverman, M. Stitzer, and D. Svikis. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 61: 297-306 (2001).
29. J. Towt, S. Tsai, M. Hernandez, A. Klimov, C. Kravec, S. Rouse, H. Subuhi, B. Twarowska, and S. Salamone. On-Track Test Cup: a novel, on-site, multi-analyte screen for the detection of abused drugs. J. Anal. Toxicol. 19: 504-510 (1995).
30. C. Murphy and M. Huestis. LC - ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-β-D-glucuronide, morphine-6-β-D- glucuronide, and codeine-6-β-D-glucuronide in human urine. J. Mass Spectrom. 40: 1412-416 (2005).
31. SAMHSA, Mandatory Guidelines for Federal Workplace Drug Testing Programs; notice, Vol. 73, 2008, Substance Abuse and Mental Health Services Administration, HHS, Rockville, MD.
32. T. Breindahl and K. Andreasen. Determination of 11-nor-delta9- tetrahydrocannabinol-9-carboxylic acid in urine using high-performance liquid chromatography and electrospray ionization mass spectrometry. J. Chromatogr. B 732: 155-64 (1999).
33. H. Hoja, P. Marquet, B. Verneuil, H. Lotfi, B. Penicaut, and G. Lachatre. Applications of liquid chromatography - ass spectrometry in analytical toxicology: a review. J. Anal. Toxicol. 21: 116-26 (1997).
34. R. Dams, T. Benijts,W. Lambert, and A. De Leenheer. Sonic spray ionization technology: performance study and application to a LC/MS analysis on a monolithic silica column for heroin impurity profiling. Anal. Chem. 74: 3206-212 (2002).
35. R. Dams, R. Choo, W. Lambert, H. Jones, and M. Huestis. Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients. Drug Alcohol Depend. 87: 258-67 (2007).
36. E. Rook, M. Hillebrand, and H. Rosing. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high performance liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B 824: 213-221 (2005).
37. A. Al-Asmari and R. Anderson. Method for quantification of opiates and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 31: 394-408 (2007).
38. E. Cone, A. Sampson-Cone,W. Darwin, M. Huestis, and J. Oyler. Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J. Anal. Toxicol. 27: 386-401 (2003).
39. P. Kintz, C. Sengler,V. Cirimele, and P. Mangin. Evidence of crack use by anhydroecgonine methylester identification. Hum Exp. Toxicol. 16: 123-127 (1997).
40. D. Isenschmid, M. Fischman, R. Foltin, and Y. Caplan. Concentration of cocaine and metabolites in plasma of humans following intravenous administration and smoking of cocaine. J. Anal. Toxicol. 16: 311-314 (1992).
41. D. Stewart, T. Inaba, B. Tang, and W. Kalow. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20: 1557-1563 (1997).
42. R. Lewis, R. Johnson, M. Angier, and R. Ritter. Determination of cocaine, its metabolites, pyrolysis products, and ethanol adducts in postmortem fluids and tissues using Zymark® automated solid phase extraction and gas chromatography mass spectrometry. J. Chromatogr. B 806: 141-150 (2004).
43. P. Cardona, A. Chaturvedi, J. Soper, and D. Canfield. Simultaneous analyses of cocaine, cocaethylene, and their possible metabolic and pyrolytic products. Forensic Sci. Int. 157: 46-56 (2006).
44. K. Zaitsu, A. Miki, M. Katagi, and H. Tsuchihashi. Long-term stability of various drugs and metabolites in urine, and preventive measures against their decomposition with special attention to filtration sterilization. Forensic Sci. Int. 174: 189-196 (2008).
45. D. Isenschmid, B. Levine, and Y. Caplan. A comprehensive study of the stability of cocaine and its metabolites. J. Anal. Toxicol. 13: 250-256 (1989).
46. E. Shimomura, G. Hodge, and B. Paul. Examination of postmortem fluids and tissues for the presense of methylecgonidine, ecgonidine, cocaine, and benzoylecgonine using solid-phase extraction and gas chromatography mass spectrometry. Clin. Chem. 47: 1040-1047 (2001).
47. A. Fandino, S. Toennes, and G. Kauert. Studies on in vitro degradation of anhydroecgonine methylester in human plasma. J. Anal. Toxicol. 26: 567-570 (2002).
48. S. Toennes, A. Fandino, F. Hesse, and G. Kauert. Artifact production in the assay of anhydroecgonine methylester in serum using gas chromatography mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 792: 345-351 (2003).
49. S. Toennes, A. Fandino, G. Kauert. Gas chromatography mass spectrometry detection of anhydroecgonine methylester in human serum as evidence of recent smoking of crack. J. Chromatogr. B Biomed. Sci. Appl. 735: 127-132 (1999).
50. R. de la Torre, J. Ortuno, M. Gonzalez, M. Farre, J. Gami, and J. Segura. Determination of cocaine and its metabolites in human urine by gas chromatography mass spectrometry after simultaneous use of cocaine and ethanol. J. Pharm. Biomed.Anal. 13: 305-312 (1995).
51. R. Dean, E. Harper, N. Dumaual, D. Stoeckel, and W. Bosron. Effect of ethanol on cocaine metabolism: formation of cocaethylene and norcocaethylene. Toxicol. Appl. Pharmacol. 117: 1-8 (1992).
52. B. Paul, S. Lalani, T. Bosy, A. Jacobs, and M. Huestis. Concentration profiles of cocaine, pyrolytic methyl ecgonidine and thirteen metabolites in human blood and urine: determination by gas chromatography-mass spectrometry. Biomed. Chromatogr. 19: 677-688 (2005).